Adrienne M Keener1,2, Kimberly C Paul3, Aline Folle3, Jeff M Bronstein1, Beate Ritz1,3. 1. Department of Neurology, UCLA David Geffen School of Medicine, Los Angeles, CA, USA. 2. Department of Neurology, Veterans Administration Greater Los Angeles Healthcare System, Los Angeles, CA, USA. 3. Department of Epidemiology, UCLA Fielding School of Public Health, Los Angeles, CA, USA.
Abstract
BACKGROUND: Parkinson's disease (PD) is a heterogeneous disorder with variability in phenotype and progression. OBJECTIVE: We describe characteristics of PD patients in the largest population-based cohort followed for progression to date, and evaluate clinical risk factors for cognitive impairment and mortality. METHODS: We collected longitudinal data using the Unified Parkinson's Disease Rating Scale (UPDRS), Mini-Mental State Exam (MMSE), and Geriatric Depression Scale (GDS) in 242 new-onset PD patients followed for progression. We compared those who developed cognitive impairment (MMSE≤24) with those who did not, using t-tests, chi-square tests, and Cox proportional hazards regression. Mortality risk factors were assessed in all 360 patients enrolled at baseline. RESULTS: Thirty-four patients developed cognitive impairment during follow-up. Baseline characteristics predictive of faster time to cognitive impairment were older age at diagnosis, fewer years of education, and longer average sleep duration reported. The 197 patients who died were older at diagnosis, reported longer average sleep duration, had lower baseline MMSE scores, higher UPDRS-III scores, and a higher proportion were of the postural instability gait difficulty (PIGD) subtype. Patients with the tremor dominant (TD) subtype at baseline were less likely to develop cognitive impairment or die during follow-up. Progression of cognitive, depressive, and motor symptoms occurred in parallel. CONCLUSIONS: Motor symptom severity and subtype influence the incidence of cognitive impairment and mortality in PD, with the TD motor subtype being relatively protective. In addition, we newly found that longer average sleep duration at baseline predicts faster progression to cognitive impairment and mortality.
BACKGROUND:Parkinson's disease (PD) is a heterogeneous disorder with variability in phenotype and progression. OBJECTIVE: We describe characteristics of PDpatients in the largest population-based cohort followed for progression to date, and evaluate clinical risk factors for cognitive impairment and mortality. METHODS: We collected longitudinal data using the Unified Parkinson's Disease Rating Scale (UPDRS), Mini-Mental State Exam (MMSE), and Geriatric Depression Scale (GDS) in 242 new-onset PDpatients followed for progression. We compared those who developed cognitive impairment (MMSE≤24) with those who did not, using t-tests, chi-square tests, and Cox proportional hazards regression. Mortality risk factors were assessed in all 360 patients enrolled at baseline. RESULTS: Thirty-four patients developed cognitive impairment during follow-up. Baseline characteristics predictive of faster time to cognitive impairment were older age at diagnosis, fewer years of education, and longer average sleep duration reported. The 197 patients who died were older at diagnosis, reported longer average sleep duration, had lower baseline MMSE scores, higher UPDRS-III scores, and a higher proportion were of the postural instability gait difficulty (PIGD) subtype. Patients with the tremor dominant (TD) subtype at baseline were less likely to develop cognitive impairment or die during follow-up. Progression of cognitive, depressive, and motor symptoms occurred in parallel. CONCLUSIONS: Motor symptom severity and subtype influence the incidence of cognitive impairment and mortality in PD, with the TD motor subtype being relatively protective. In addition, we newly found that longer average sleep duration at baseline predicts faster progression to cognitive impairment and mortality.
Authors: K Berger; M M Breteler; C Helmer; D Inzitari; L Fratiglioni; C Trenkwalder; A Hofman; L J Launer Journal: Neurology Date: 2000 Impact factor: 9.910
Authors: Gail A Kang; Jeff M Bronstein; Donna L Masterman; Matthew Redelings; Jarrod A Crum; Beate Ritz Journal: Mov Disord Date: 2005-09 Impact factor: 10.338
Authors: Julius B M Anang; Jean-Francois Gagnon; Josie-Anne Bertrand; Silvia Rios Romenets; Veronique Latreille; Michel Panisset; Jacques Montplaisir; Ronald B Postuma Journal: Neurology Date: 2014-08-29 Impact factor: 9.910
Authors: Caroline H Williams-Gray; Sarah L Mason; Jonathan R Evans; Thomas Foltynie; Carol Brayne; Trevor W Robbins; Roger A Barker Journal: J Neurol Neurosurg Psychiatry Date: 2013-06-18 Impact factor: 10.154
Authors: Yu-Hsuan Chuang; Ake T Lu; Kimberly C Paul; Aline D Folle; Jeff M Bronstein; Yvette Bordelon; Steve Horvath; Beate Ritz Journal: J Parkinsons Dis Date: 2019 Impact factor: 5.568